253994-281-T: Colorectal Cancer
Patient-Derived Models Repository
| Patient | |
|---|---|
| Sex | Male |
| Age at Time of Collection | 37 |
| Race / Ethnicity | / Not Hispanic or Latino |
| Patient Tumor | |
|---|---|
| Histology | Colorectal Cancer |
| Primary Tissue | Digestive/Gastrointestinal |
| Collection Site | Not Specified |
| Tumor Type | Metastatic |
| Grade | Low grade ( Classification: ) |
| Stage | Not Specified |
| PDX model Engraftment | |||||
|---|---|---|---|---|---|
| Host Strain Name | Site | Type | Material | Material Status | Passage |
| NOD scid gamma | Subcutaneous (flank) | Heterotopic | Not Specified | Not Specified | 0, 1, 2, 3, 4, Not Specified |
| Model Quality Control | ||
|---|---|---|
| Technique | Description | Passage |
| Histology | Model validated against histological features of same diagnosis | All |
| Fingerprinting | Model validated against patient tumour or P0 xenograft | All |
| Human mouse/DNA | Model validated against patient tumour or P0 xenograft | All |
| Collection (Current Model) | |
|---|---|
| Age | 37 |
| Diagnosis | Colorectal Cancer |
| Type | Metastatic |
| PDX Mouse | 253994-281-T |
| Collection Site | Not Specified |
| Sex | Male |
|---|---|
| Race / Ethnicity | Not specified / Not Hispanic or Latino |
| Date Regimen Started | Regimen | Dose | Best Response | Duration (Months) |
|---|---|---|---|---|
| 2014-07-01 | Fluorouracil | Not Specified | Disease Progression | null Months |
| 2014-10-01 | Fluorouracil and Irinotecan and Leucovorin and Ziv-Aflibercept | Not Specified | Disease Progression | 3 Months / 3 Months / 3 Months / 3 Months |
| 2015-08-01 | Regorafenib | Not Specified | Disease Progression | 1 Months |
| 2013-11-01 | Bevacizumab and Fluorouracil and Leucovorin | Not Specified | Disease Progression | 8 Months / 8 Months / 8 Months |
| 2015-05-01 | Bevacizumab and Capecitabine | Not Specified | Disease Progression | 1 Months / 1 Months |
| 2015-06-01 | Sorafenib | Not Specified | Disease Progression | 2 Months |
| 2015-04-01 | Regorafenib | Not Specified | Disease Progression | 1 Months |
| 2014-07-01 | Bevacizumab and Fluorouracil and Leucovorin | Not Specified | Disease Progression | 1 Months / 1 Months / 1 Months |
| 2015-01-01 | Bevacizumab and Fluorouracil and Leucovorin Calcium and Oxaliplatin | Not Specified | Disease Progression | 3 Months / 3 Months / 3 Months / 3 Months |
| 2014-05-01 | Bevacizumab | Not Specified | Disease Progression | 1 Months |
| 2013-06-01 | Bevacizumab and Fluorouracil and Leucovorin Calcium and Oxaliplatin | Not Specified | Disease Progression | 5 Months / 5 Months / 5 Months / 5 Months |
| 2015-08-01 | Capecitabine | Not Specified | Disease Progression | 1 Months |
| Sample ID | Sample Type | Engrafted Tumor Passage | Data Type | Data Available | Platform Used | Raw Data |
|---|---|---|---|---|---|---|
| E85M207E17 | Engrafted Tumor | Passage 2 | mutation | View data | NCI cancer gene panel NCI cancer gene panel | Not available |
| E85M208 | Engrafted Tumor | Passage 1 | mutation | View data | NCI cancer gene panel NCI cancer gene panel | Not available |
| E85M209EE3F36A35 | Engrafted Tumor | Passage 4 | mutation | View data | NCI cancer gene panel NCI cancer gene panel | Not available |
| E85M209 | Engrafted Tumor | Passage 1 | mutation | View data | NCI cancer gene panel NCI cancer gene panel | Not available |
Sample ID: Histology: Tumor Type: Engrafted Tumor Passage: Platform:
